Investor Presentaiton

Investor presentation First three months of 2017 Slide 94 Global haemophilia market is growing by high-single digit Sales of recombinant coagulation factors Strategic positioning of Novo Nordisk's haemophilia portfolio NovoSevenⓇ Coagil VII® RecombinateⓇ/AdvateⓇ KogenateⓇ/HelixateⓇ ObizurⓇ1 35 XynthaⓇ/RefactoⓇ Eloctate® NovoEight® Idelvion® RixubisⓇ Novo Nordisk compound Status Strategic position Alprolix® Benefix® NovoSevenⓇ Launched Maintain market leadership DKK 30 billion NovoEight® Launched 25 Establish presence in a competitive market place 20 N8-GP Phase 33 Contribute to market conversion 15 CAGR²: 4% CAGR²: 10% CAGR²: 16% N9-GP 10 Filed4 Establish new treatment paradigm 5 NovoThirteenⓇ Launched Launch first recombinant product 0 2011 2016 2011 2016 rFVIII rFIX 2011 2016 rFVIIa 1 ObizurⓇ only indicated for acquired haemophilia 2 CAGR for 5-year period changing diabetes® 3 Submission of N8-GP expected 2018 pending expansion of production capacity 4 Positive opinion received by CHMP in March 2017; Submitted to the US Food and Drug Administration in May 2016 novo nordisk

View entire presentation